+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 163 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.

Age: 18Years +All GendersPhase 2Phase 3
51 locations
P

Actively Recruiting

Researchers are conducting a Phase 1, open-label, multicenter clinical study to evaluate the safety, pharmacokinetics, and preliminary efficacy of HMPL-506 in patients with hematological malignancies. The study focuses on patients with specific genetic alterations in blood cancers, including relapsed or refractory Acute Myeloid Leukemia AML, Acute Lymphocytic Leukemia ALL, and multiple myeloma MM. The trial is sponsored by Hutchmed and aims to enroll between 60 and 132 patients across two phases dose escalation and dose expansion. In the dose escalation phase, approximately 30 to 38 patients with MLL-rearranged andor NPM1-mutant relapsedrefractory AML or ALL will receive escalating oral doses of HMPL-506 once daily. Starting at 50 mg, doses may increase based on safety, efficacy, and pharmacokinetic data, with adjustments guided by a Safety Monitoring Committee. The dose expansion phase will enroll about 30 to 60 patients divided into three cohorts based on specific genetic markers or disease type. Patients in this phase will receive the recommended phase 2 dose in 28-day cycles until disease progression, unacceptable toxicity, or other study endpoints. Participants will undergo regular assessments including bone marrow aspiration and biopsy, safety monitoring for dose-limiting toxicities and adverse events, and evaluations of anti-tumor efficacy every treatment cycle. Pharmacokinetic and pharmacodynamic analyses will be conducted, along with electrocardiograms and laboratory tests. Safety follow-up will continue up to 42 months after the last dose. The study includes monitoring for serious adverse events and overall survival, with participants remaining under medical supervision throughout the trial duration.

Age: 18Years +All GendersPhase 1
16 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.

Age: 18Years - 75YearsAll GendersPhase 3
77 locations
S

Actively Recruiting

Researchers are studying LBL-034 in patients with relapsed or refractory multiple myeloma RRMM and plasma cell leukemia PCL to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and effectiveness. This open-label, multicenter phase III study includes dose escalation and dose expansion phases to find the recommended dose and dosing schedule. The trial aims to assess treatment response and adverse events in these patients. LBL-034 is given as an intravenous infusion every two weeks. The phase I study involves dose escalation to assess safety and tolerability, including a dose-limiting toxicity observation period lasting four weeks after the first full dose. After determining the recommended phase 2 dose RP2D, the phase II study evaluates efficacy across four patient cohorts, with dosing regimens based on phase I data. Biological samples are collected throughout for additional testing. Participants will be monitored for treatment response, drug levels, immune reaction, and side effects from the time they consent until 30 to 90 days after stopping the drug. Evaluation includes measurement of objective response rate, dose-limiting toxicities, maximum tolerated dose, adverse events, and other key outcomes such as minimal residual disease and soluble BCMA levels. The study will enroll approximately 342 patients and continues until 2027.

Age: 18Years +All GendersPhase 1Phase 2
21 locations
O

Actively Recruiting

Researchers are evaluating the safety and effects of marstacimab, a study medicine, for treating hemophilia in male pediatric patients aged 1 to 17 years. The study focuses on severe Hemophilia A and moderately severe to severe Hemophilia B, including participants with or without inhibitors. Enrollment is done sequentially by age groups starting with adolescents, then children aged 6 to 11 years, followed by children aged 1 to 5 years. All participants will receive weekly subcutaneous injections of marstacimab, initially administered at the study site with subsequent doses given either at home or at the study site over a 12-month treatment period. The study compares participants experiences during treatment to their historical bleeding and treatment records to assess how marstacimab may help prevent bleeding episodes common in hemophilia. Participants will be involved for about 14 months, including a screening period of roughly one month, 12 months of treatment, and a one-month follow-up. They will attend at least 10 study visits, with the option of completing two visits at home if regulations allow, and receive six scheduled phone calls approximately every two months. Researchers will monitor bleeding rates, safety events, immune responses, joint health, and quality of life during this time.

Age: 1Year - 17YearsMALEPhase 3
63 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQH3906 capsules, a once-daily oral medication, in adults aged 18 to 75 with moderate to severe plaque psoriasis. This multicenter, randomized, double-blind, placebo- and active-controlled Phase III trial compares TQH3906 with deucravacitinib and placebo. TQH3906 selectively inhibits TYK2, targeting inflammatory pathways involved in psoriasis, aiming to support its approval for treating this condition. Participants are randomly assigned in a 221 ratio to receive TQH3906 capsules 24 mg, deucravacitinib tablets 6 mg, or placebos matching each drug during a 16-week double-blind treatment phase. After this, all participants enter a 36-week open-label extension where they receive TQH3906 capsules alone. Following treatment, there is a 4-week safety follow-up period to monitor any lasting effects. Throughout the study, participants undergo regular assessments including the static Physicians Global Assessment sPGA and Psoriasis Area and Severity Index PASI to measure skin improvement up to 16 and 52 weeks. Additional evaluations focus on scalp, nail, and palmoplantar psoriasis, quality of life via the Dermatology Life Quality Index DLQI, and drug levels in the body. Safety is closely monitored during and after the treatment periods to gather comprehensive data over a year.

Age: 18Years - 75YearsAll GendersPhase 3
45 locations
R

Actively Recruiting

This research aims to evaluate the effects of TQH3906 Capsules in adults with active Psoriatic Arthritis PsA. The study plans to enroll 156 participants to assess how different doses of TQH3906 compare to placebo in improving PsA symptoms at Week 12, focusing on the proportion of participants reaching a 20% improvement according to the American College of Rheumatology criteria. Participants will be randomly assigned to receive one of several oral treatments daily from Day 1 to Day 169. These include 24 mg or 16 mg doses of TQH3906 capsules, a placebo phase followed by TQH3906, or an active comparator, Tofacitinib Citrate tablets. The study uses a double-blind design to compare these treatments effects and safety. Throughout the study, participants will attend visits for assessments including the ACR improvement criteria at multiple time points up to Day 169. Blood samples will be collected to evaluate drug levels and immune markers, and safety will be monitored closely. The main outcome is the proportion of participants achieving ACR20 response at Week 12. The study duration extends up to November 2027, with detailed evaluations of drug effects and adverse events throughout.

Age: 18Years - 70YearsAll GendersPhase 2
44 locations
G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
T

Actively Recruiting

Researchers are evaluating a new tuberculosis preventive treatment among adolescents and school staff who have been in close contact with active TB cases. This study compares a novel 1-month ultra-short regimen called 1H3P3 with the standard 3-month 3HR regimen, aiming to prevent latent TB infection from progressing to active tuberculosis. The trial is a phase 3, multi-center, open-label, cluster randomized controlled study conducted in school settings in China, with the goal of improving TB prevention strategies for adolescents. Participants are randomly assigned to receive either the 12-dose 1H3P3 regimen of isoniazid and rifapentine taken three times a week for one month, or the 3HR regimen of isoniazid and rifampicin taken once daily for three months. Close contacts of TB cases are screened using blood tests, chest X-rays, sputum testing, and symptom checks to rule out active TB before enrollment. The treatment period lasts either one or three months depending on the group, followed by two years of follow-up to monitor for TB development. During the study, participants will undergo regular assessments including monitoring for active tuberculosis through clinical and laboratory tests, adverse events, treatment adherence, and drug resistance if active TB occurs. The main measurement is the cumulative incidence of active TB over 24 months after treatment begins. Safety and treatment completion rates are tracked throughout. Participation involves screening, treatment administration, and periodic follow-up visits over two years to evaluate outcomes and overall TB prevention effectiveness.

Age: 13Years +All GendersPhase 3
66 locations

1-10 of 163

1